Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

Yoshikuni Mizuno; Nobuo Yanagisawa; Sadako Kuno; Mitsutoshi Yamamoto; Kazuko Hasegawa; Hideki Origasa; Hisayuki Kowa; Japanese Pramipexole Study Group

doi:10.1002/mds.10508

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

Mov Disord. 2003 Oct;18(10):1149-56. doi: 10.1002/mds.10508.

Authors

Yoshikuni Mizuno¹, Nobuo Yanagisawa, Sadako Kuno, Mitsutoshi Yamamoto, Kazuko Hasegawa, Hideki Origasa, Hisayuki Kowa; Japanese Pramipexole Study Group

Affiliation

¹ Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan. y_Mizuno@med.juntendo.ac.jp

PMID: 14534919
DOI: 10.1002/mds.10508

Abstract

We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Activities of Daily Living
Aged
Antiparkinson Agents / therapeutic use*
Benzothiazoles
Bromocriptine / therapeutic use*
Demography
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug Tolerance
Female
Humans
Male
Middle Aged
Parkinson Disease / drug therapy*
Pramipexole
Prospective Studies
Quality of Life
Thiazoles / therapeutic use*
Time Factors
Treatment Outcome

Substances

Antiparkinson Agents
Benzothiazoles
Thiazoles
Bromocriptine
Pramipexole